Adenosquamous Lung Carcinoma
Associated Genetic Biomarkers
NCI Definition: An aggressive carcinoma with a poor prognosis characterized by a presence of both malignant squamous cells and glandular cells. 
Adenosquamous lung carcinomas most frequently harbor alterations in TP53, KRAS, EGFR, MET, and PIK3CA .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in adenosquamous lung carcinoma .
There are 2 clinical trials for adenosquamous lung carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain adenosquamous lung carcinoma as an inclusion criterion, 1 is phase 2 (1 open) and 1 is phase 3 (1 open).
EGFR and KRAS are the most frequent gene inclusion criteria for adenosquamous lung carcinoma clinical trials .
Carboplatin, nab-paclitaxel, and placebo are the most common interventions in adenosquamous lung carcinoma clinical trials.
Significant Genes in Adenosquamous Lung Carcinoma
KRAS is altered in 18.87% of adenosquamous lung carcinoma patients .
KRAS is an inclusion eligibility criterion in 1 clinical trial for adenosquamous lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and adenosquamous lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.